• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22857 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     Andalusian Health Technology Assessment Area (AETSA) [Mechanical thrombectomy with MERCI device. Ischaemic stroke]
2010     Committee for New Health Technology Assessment (CNHTA) [Mechanical thrombectomy using Penumbra system for acute ischemic stroke in intracranial artery]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Mechanical percutaneous transluminal cerebral clot retrieval in acute ischemic stroke]
2010     Finnish Office for Health Care Technology Assessment (Finohta) [Mechanical non-invasive cough assist device]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Mechanical devices for urinary incontinence]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Measurement of the fraction of exhaled nitric oxide in the diagnosis and treatment of asthmatic children]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement of preference in parodontopathy]
2015     Haute Autorite de sante (HAS) [Measurement of nitric oxide (NO) in exhaled air]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement of myocardial fractional flow reserve (FFR) in coronary heart disease]
2019     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Measurement of gastric residual volume during enteral feeding in patients hospitalized in the intensive care unit]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Measurement of fractional flow reserve to guide the decision on percutaneous coronary interventions]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure - Addendum to Commission E15-04]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary arterial pressure by means of implanted sensor for treatment optimization in heart failure stage NYHA III]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Measles: diagnosis and detection]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Matrix-assisted laser desorption/ionization-time of flight analyzer (MALDI-TOF) in infections]
2005     Finnish Office for Health Care Technology Assessment (Finohta) [Maternal ultrasound and serum screening in the detection of structural and chromosomal abnormalities]
2023     Basque Office for Health Technology Assessment (OSTEBA) [Massive parallel sequencing for the diagnosis of acute leukaemia]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Mason's vertical banded gastroplasty and other gastroplasties in treating obesity]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Markerless real-time monitoring surface guided radiation therapy]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Maribavir (cytomegalovirus infection (treatment-refractory)) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Maralixibat (cholestatic pruritis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Map on shared resources in HTA and Health Services]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Map on shared resources in health technology assessment]
2009     Andalusian Health Technology Assessment Area (AETSA) [Manual to adapt health technology assessment reports to the public (MADETSCI)]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Manual suture versus mechanical suture for surgery of colorectal anastomosis]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mandibular advancement devices in mild to moderate obstructive sleep apnoea in adults]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Management of the extravasation of antineoplastic agents]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Management of patients with dyspepsia]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Management of elderly patients with chronic pathologies]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Management and improvement in cancer pain: focusing on narcotic analgesics]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Mammography screening in the county of Funen 1993 - 1997. An HTA report]
2010     Andalusian Health Technology Assessment Area (AETSA) [Mammaprint]
2007     Norwegian Knowledge Centre for the Health Services (NOKC) [Male infertility: intracytoplasmic sperm injection (ICSI) using surgically retrieved sperm from the testis or the epididymis]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [MALDI-TOF mass spectrometry technology in the diagnosis of antibiotic resistance]
2008     Committee for New Health Technology Assessment (CNHTA) [Malaria antigen, rapid]
2009     Committee for New Health Technology Assessment (CNHTA) [Malaria antigen, rapid(target Ag:Aldolase,Histidine-rich protein-2)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic sphincter augmentation for gastrooesophageal reflux disease]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic sphincter augmentation for gastrooesophageal reflux disease (Addendum to Commission E21-06)]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Magnetic resonance-compatible pacemakers]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Magnetic resonance imaging-guided transurethral ultrasound ablation of prostatic hyperplasia]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Magnetic resonance imaging-guided transurethral ultrasound ablation of localized prostate cancer]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine myoma: (2. Addendum to Commissions E14-04 and E14-05)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine myoma (Addendum to Commissions E14-04 and E14-05)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]
2012     Finnish Office for Health Care Technology Assessment (Finohta) [Magnetic resonance imaging of primary breast cancer]
2008     Committee for New Health Technology Assessment (CNHTA) [Magnetic Resonance Imaging guided high intensity Focused Ultrasound Surgery(MRgFUS) using ExAblate 2000 equipment]
2008     Andalusian Health Technology Assessment Area (AETSA) [Magnetic Resonance imaging for breast cancer diagnostics. Systematic review and economic assessment]
2012     Andalusian Health Technology Assessment Area (AETSA) [Magnetic resonance guided focused ultrasound for uterine myomas ablation]
2009     Committee for New Health Technology Assessment (CNHTA) [Magnetic remote controlled catheter navigation technique]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Magnetic growth rods for the scoliosis treatment in children]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Macitentan (pulmonary arterial hypertension) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Macitentan - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2019     Haute Autorite de sante (HAS) [Lymphoseek (tilmanocept), radiopharmaceutical for diagnostic use]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Lyme disease and persistent symptoms: a look at the current knowledge and recommendations for improving management]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Lutetium-177 radiolabeled somatostatin analogs in neuroendocrine tumors]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Lutetium 177 PSMA in patients with prostate cancer]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (non-transfusion-dependent beta-thalassaemia) - Addendum to Commission A23-20]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndromes) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndrome) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (beta-thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lusotrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lurasidone - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Lung cryobiopsy in diffuse interstitial lung disease diagnosis]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Lung cancer: investigation, treatment and follow-up algorithms]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lung cancer screening]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lung cancer screening using low-dose computed tomography]
2020     Austrian Institute for Health Technology Assessment (AIHTA) [Lung cancer screening in risk groups]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumasiran (hyperoxaluria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Lumacaftor/Ivacaftor therapy in cystic fibrosis]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis, homozygous F508del mutation in the CFTR gene, 2-5 years) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis, 1 to < 2 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis in children aged 2 to 5 years) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Lower Urinary Tract Symptoms - epidemiology and results from LUTS project Funen on implementation of a clinical guideline in general practice]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Lower respiratory tract infections of a viral origin in the paediatric population: systematic review of Spanish literature]
2023     National Evidence-based Healthcare Collaborating Agency (NECA) [Low-level light therapy for primary dysmenorrhea]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Low-intensity ultrasound for the treatment of fractures]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Low-intensity pulsed ultrasound for the treatment of pseudarthrosis]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Low-dose computed tomography screening for lung cancer]
1999     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Low-back pain: frequency, management and prevention from an HTA perspective]
2002     Basque Office for Health Technology Assessment (OSTEBA) [Low molecular weight heparins versus traditional heparins in thromboembolic diseases]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Low density lipoprotein apheresis as adjuvant treatment for familial hypercholesterolaemia]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Longevity of dental amalgam in comparison to composite materials]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [Long-term safety and stability of refractive surgeries in myopia]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Long-acting insulin analogues in the treatment of diabetes mellitus type 2]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Long-acting insulin analogues in the treatment of diabetes mellitus type 1]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Long term substitution treatment (maintenance treatment) of opioid dependent persons]